Parkinson's Medical Necessity Requirements: What Your Doctor Must Document for Approval
Prior authorization denials in Parkinson's disease usually happen because a specific chart phrase (such as a ≥ 30% ON/OFF UPDRS Part III levodopa challenge for DBS, diagnostic uncertainty vs. Essential Tremor for DaTscan, or Jimmo v. Sebelius maintenance necessity for LSVT therapy) was omitted from the clinical note. Use these sourced checklists before your clinic submits the request:
Accuracy Level — Tier 1 Published Prices: You are currently viewing general published hospital cash prices, Medicare baselines, and multi-payer ranges. Add your insurance card to unlock Tier 2 plan pricing and Tier 3 verified benefit checks.
Deep Brain Stimulation (DBS) Surgery — Medical Necessity & Prior Authorization Checklist
To get unilateral or bilateral Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) or globus pallidus interna (GPi) approved, Medicare and major commercial insurers require your movement-disorder team to document the following 6 clinical criteria in your medical record:
Covers unilateral or bilateral thalamic (VIM) DBS for disabling tremor and STN/GPi DBS for patients with levodopa-responsive Parkinson's disease whose symptoms are not adequately controlled by medication (Hoehn & Yahr ≥ 2).
Official Policy ReferenceRequires ≥ 4 years disease duration (standard PD), documented ON/OFF UPDRS Part III improvement ≥ 30%, refractory motor complications or tremor, and neuropsychological clearance.
Official Policy ReferenceRequires idiopathic PD with disabling motor fluctuations/dyskinesia or refractory tremor despite optimal pharmacotherapy, UPDRS Part III improvement ≥ 30% on levodopa challenge, and no severe cognitive impairment.
Official Policy ReferenceCovers STN or GPi stimulation for levodopa-responsive idiopathic PD (Hoehn & Yahr ≥ 2 when OFF) with disabling motor fluctuations or dyskinesia unresponsive to medical therapy.
Official Policy ReferenceRequires documented levodopa responsiveness, persistent disabling motor complications or tremor despite medical therapy, and absence of dementia.
Official Policy ReferenceRequires evaluation by a Kaiser Movement Disorder Neurologist, formal ON/OFF levodopa motor testing, neuropsychology clearance, and multidisciplinary DBS conference approval.
Official Policy ReferenceDaTscan (Ioflupane I-123 SPECT) — Medical Necessity & Prior Authorization Checklist
Insurers approve DaTscan ONLY when a clinical exam alone cannot distinguish presynaptic Parkinsonian syndrome from non-degenerative tremor (such as Essential Tremor or drug-induced parkinsonism). Routine ordering to 'confirm' classic Parkinson's is the #1 reason DaTscan claims are denied. Document these 4 items:
Covered for striatal dopamine transporter visualization in adult patients with suspected Parkinsonian syndromes (ICD-10 G20, G21.x, G25.0) to differentiate essential tremor from tremor due to presynaptic parkinsonian syndromes.
Official Policy ReferenceMedically necessary when clinical examination is inconclusive between Parkinsonian syndrome and Essential Tremor or drug-induced parkinsonism, and results will guide pharmacotherapy.
Official Policy ReferenceCovers DaTscan to differentiate essential tremor from tremor due to idiopathic PD, MSA, or PSP; considers repeat DaTscans for monitoring disease progression not medically necessary.
Official Policy ReferenceRequires specialist evaluation documenting equivocal clinical features between Parkinsonian syndrome and non-parkinsonian tremor.
Official Policy ReferenceCovered for diagnostic differentiation of uncertain Parkinsonian tremor vs. Essential Tremor.
Official Policy ReferencePT, OT & Speech Therapy (LSVT BIG, LSVT LOUD & Swallow Studies) — Medical Necessity Checklist
A standard LSVT BIG or LSVT LOUD course requires 16 one-hour 1-on-1 sessions (4 days/week for 4 weeks). Furthermore, under the federal Jimmo v. Sebelius settlement, Medicare CANNOT deny therapy simply because Parkinson's is progressive and the goal is to maintain function or slow decline rather than 'cure' the patient. Document these 5 items:
Skilled therapy is covered when needed to maintain the patient's current condition or prevent/slow further deterioration, even when full restoration is not expected. Claims above the $2,480 CY 2026 threshold require the KX modifier; targeted medical review begins at $3,000.
Official Policy ReferenceCovers medically necessary PT, OT, and Speech therapy for neurological impairments (gait instability, dysphagia, hypophonia). Watch for employer ERISA plan hard visit caps (20–60 visits/year); state-regulated CA plans must cover medically necessary rehabilitative services under Essential Health Benefits.
Official Policy ReferenceHome Health & In-Home Neuromuscular Rehab — Medical Necessity Checklist
Medicare Part A/B covers intermittent skilled Home Health Physical, Occupational, and Speech Therapy at a $0 patient copay — but ONLY if the patient meets Medicare's two-part 'Homebound' and 'Skilled Need' criteria:
$0 copay for intermittent skilled nursing, PT, OT, and speech-language pathology when the beneficiary is confined to the home ('homebound') and under a physician's plan of care. Maintenance therapy is covered under Jimmo v. Sebelius.
Official Policy ReferenceDuopa (PEG-J Pump) & Vyalev (24-Hr Subcutaneous Infusion) — Medical Necessity Checklist
Because Duopa and Vyalev cost $85,000–$130,000+ per year at list price, Medicare and commercial insurers require strict documentation that oral medications can no longer control the patient's daily 'OFF' periods:
Duopa is covered under the Part B Durable Medical Equipment external infusion pump benefit for advanced levodopa-responsive PD with severe motor fluctuations; Vyalev is covered under Part D Specialty formulary/exception criteria (subject to the $2,100 annual Part D cap).
Official Policy ReferenceRequires prescription by a neurologist, confirmed levodopa responsiveness, persistent OFF time despite oral carbidopa/levodopa plus ≥ 2 adjunctive drug classes, and no concurrent non-selective MAO inhibitor use.
Official Policy ReferenceBrand & Specialty Parkinson's Drugs (Rytary, Neupro, Xadago, Gocovri, Apokyn, Nourianz, Nuplazid) — Prior Auth Checklist
Every Medicare Part D plan and commercial PBM uses Step Therapy and Prior Authorization on brand-name Parkinson's medications. Before your neurologist submits the PA form, make sure the chart note explicitly documents the exact step-therapy prerequisites below:
Part D plans must issue a standard coverage determination within 72 hours (or 24 hours for an expedited request when waiting could jeopardize health). Once approved, all out-of-pocket costs count toward the $2,100 CY 2026 Part D cap.
Official Policy ReferenceMedi-Cal Rx adjudicates all PA requests within 24 hours (California statutory turnaround). Approved brand/specialty medications carry a $0 patient copay.
Official Policy Reference